From lifesaving Hepatitis C medicines that only a fraction of people in need can afford, to overnight price hikes on decades-old medicines, to growing resistance to existing antibiotic treatments, the rising price of medicines and lack of patient-focused research and development is a crisis that can no longer be ignored.
In our field programs every day, Doctors Without Borders/Médecins Sans Frontières (MSF) not only grapples with the high price of medicines and vaccines, but also with a lack of research and development for neglected patients.
But it doesn’t have to be this way. In a special October 26 webcast, a panel of international and US experts took a deeper look at the causes and consequences of high-priced medicines globally, and opportunities to improve a system that is failing patients who urgently need access to effective and affordable innovation.
Panelists: Dr. Manica Balasegaram, Executive Director, MSF Access Campaign Judit Rius Sanjuan, US Manager and Legal Policy Advisor, MSF Access Campaign Tracy Swan, Hepatitis/HIV Project Director, Treatment Action Group Moderated by Sandra Murillo, Media Relations Manager, Doctors Without Borders